Novel and Future Therapeutic Drugs for Advanced Mycosis Fungoides and Sézary Syndrome
- PMID: 31192214
- PMCID: PMC6548851
- DOI: 10.3389/fmed.2019.00116
Novel and Future Therapeutic Drugs for Advanced Mycosis Fungoides and Sézary Syndrome
Abstract
Mycosis fungoides (MF) and Sézary syndrome (SS) are the most common subtypes of cutaneous T-cell lymphoma. The majority of MF cases present with only patches and plaques and the lesions are usually limited to the skin. On the other hand, in some cases, patients show skin tumors or erythroderma followed by lymph node involvement and rarely visceral organ involvement. SS is a rare, aggressive cutaneous T-cell lymphoma marked by exfoliative erythroderma, lymphadenopathy, and leukemic blood involvement. Because patients with relapsed or refractory MF/SS display a poor prognosis and the current treatment options are characterized by high rates of relapse, there is unmet need for the efficient treatment. This review provides a discussion of the recent and future promising therapeutic approaches in the management of advanced MF/SS. These include mogamulizumab, brentuximab vedotin, alemtuzumab, immune checkpoint inhibitors, IPH4102 (anti-KIR3DL2 antibody), histone deacetylase inhibitors (vorinostat, romidepsin, panobinostat, belinostat, and resminostat), pralatrexate, forodesine, denileukin diftitox, duvelisib, lenalidomide, and everolimus.
Keywords: Sézary syndrome; clinical trial; mycosis fungoides; novel therapeutic agents; peripheral T-cell lymphoma.
Figures


Similar articles
-
Cutaneous T cell Lymphoma: an Update on Pathogenesis and Systemic Therapy.Curr Hematol Malig Rep. 2015 Dec;10(4):468-76. doi: 10.1007/s11899-015-0293-y. Curr Hematol Malig Rep. 2015. PMID: 26626770 Review.
-
The Treatment of Advanced-Stage Mycosis Fungoides and Sezary Syndrome: a Hematologist's Point of View.Mediterr J Hematol Infect Dis. 2022 Mar 1;14(1):e2022029. doi: 10.4084/MJHID.2022.029. eCollection 2022. Mediterr J Hematol Infect Dis. 2022. PMID: 35444765 Free PMC article. Review.
-
Mycosis Fungoides and Sézary Syndrome: Updates and Review of Current Therapy.Curr Treat Options Oncol. 2021 Jan 7;22(2):10. doi: 10.1007/s11864-020-00809-w. Curr Treat Options Oncol. 2021. PMID: 33415447 Review.
-
Integrating novel systemic therapies for the treatment of mycosis fungoides and Sézary syndrome.Best Pract Res Clin Haematol. 2018 Sep;31(3):322-335. doi: 10.1016/j.beha.2018.07.007. Epub 2018 Jul 18. Best Pract Res Clin Haematol. 2018. PMID: 30213403 Review.
-
Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.J Am Acad Dermatol. 2014 Feb;70(2):223.e1-17; quiz 240-2. doi: 10.1016/j.jaad.2013.08.033. J Am Acad Dermatol. 2014. PMID: 24438970 Review.
Cited by
-
Single-Cell RNA Sequencing Unveils the Clonal and Transcriptional Landscape of Cutaneous T-Cell Lymphomas.Clin Cancer Res. 2022 Jun 13;28(12):2610-2622. doi: 10.1158/1078-0432.CCR-21-4437. Clin Cancer Res. 2022. PMID: 35421230 Free PMC article.
-
Combination of Resminostat with Ruxolitinib Exerts Antitumor Effects in the Chick Embryo Chorioallantoic Membrane Model for Cutaneous T Cell Lymphoma.Cancers (Basel). 2022 Feb 20;14(4):1070. doi: 10.3390/cancers14041070. Cancers (Basel). 2022. PMID: 35205818 Free PMC article.
-
Benefits and Challenges of Pre-clustered Network-Based Pathway Analysis.Front Genet. 2022 May 10;13:855766. doi: 10.3389/fgene.2022.855766. eCollection 2022. Front Genet. 2022. PMID: 35620466 Free PMC article.
-
Targeting the CD47-SIRPα Axis: Present Therapies and the Future for Cutaneous T-cell Lymphoma.Cells. 2022 Nov 13;11(22):3591. doi: 10.3390/cells11223591. Cells. 2022. PMID: 36429020 Free PMC article. Review.
-
Mycosis Fungoides and Sézary Syndrome: An Integrative Review of the Pathophysiology, Molecular Drivers, and Targeted Therapy.Cancers (Basel). 2021 Apr 16;13(8):1931. doi: 10.3390/cancers13081931. Cancers (Basel). 2021. PMID: 33923722 Free PMC article. Review.
References
-
- Agar NS, Wedgeworth E, Crichton S, Mitchell TJ, Cox M, Ferreira S, et al. . Survival outcomes and prognostic factors in mycosis fungoides/sézary syndrome: validation of the revised international society for Cutaneous Lymphomas/European Organisation for research and treatment of cancer staging proposal. J Clin Oncol. (2010) 28:4730–9. 10.1200/JCO.2009.27.7665 - DOI - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources